SHP 465

Drug Profile

SHP 465

Alternative Names: Amphetamine salts (mixed, long acting) - Shire; d,l-Amphetamine and d-amphetamine salts (long acting) - Shire; d,l-Amphetamine and dextroamphetamine salts (long acting) - Shire; d-Amphetamine and d,l-amphetamine salts (long acting) - Shire; Dextroamphetamine and d,l-amphetamine salts (long acting) - Shire; SHP-465; SLI 381 XR; SPD465; Triple-bead mixed amphetamine salts - Shire

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Shire
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Attention-deficit hyperactivity disorder

Most Recent Events

  • 19 Jan 2017 Preregistration for Attention-deficit hyperactivity disorder (In adults, In adolescents, In children) in USA (PO)
  • 19 Jan 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Attention-deficit hyperactivity disorder (In adults, In adolescents, In children) in USA (PO) is 2017-06-20
  • 19 Jan 2017 Pooled adverse events data from a phase III trial in Attention-deficit/hyperactivity disorder released by Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top